Identification and Validation of the Prognostic Panel in Clear Cell Renal Cell Carcinoma Based on Resting Mast Cells for Prediction of Distant Metastasis and Immunotherapy Response
Open accessThe DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Abstract
Clear cell renal cell carcinoma (ccRCC) has a high metastatic rate, and its incidence and mortality are still rising. The aim of this study was to identify the key tumor-infiltrating immune cells (TIICs) affecting the distant metastasis and prognosis of patients with ccRCC and to construct a relevant prognostic panel to predict immunotherapy response. Based on ccRCC bulk RNA sequencing data, resting mast cells (RMCs) were screened and verified using the CIBERSORT algorithm, survival analysis, and expression analysis. Distant metastasis-associated genes were identified using single-cell RNA sequencing data. Subsequently, a three-gene (CFB, PPP1R18, and TOM1L1) panel with superior distant metastatic and prognostic performance was established and validated, which stratified patients into high- and low-risk groups. The high-risk group exhibited lower infiltration of RMCs, higher tumor mutation burden (TMB), and worse prognosis. Therapeutically, the high-risk group was more sensitive to anti-PD-1 and anti-CTLA-4 immunotherapy, whereas the low-risk group displayed a better response to anti-PD-L1 immunotherapy. Furthermore, two immune clusters revealing distinct immune, clinical, and prognosis heterogeneity were distinguished. Immunohistochemistry of ccRCC samples verified the expression patterns of the three key genes. Collectively, the prognostic panel based on RMCs is able to predict distant metastasis and immunotherapy response in patients with ccRCC, providing new insight for the treatment of advanced ccRCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures












Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“suggest that PPP1R18 likely functions as an oncogene associated with poor prognosis in ccRCC”
From PPP1R18-mediated activation of Wnt/β-catenin and EMT is dependent on ERK signaling in clear cell renal cell carcinoma (2026) · cites this paper as [22]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106 · cited 1×
“The R package “DEseq2” [21] was used to screen DEGs between ccRCC and normal kidney samples.”
limma powers differential expression analyses for RNA-sequencing and microarray studies
Ritchie, M. E., Phipson, B., Wu, D., Hu, Y., Law, C. W., Shi, W., & Smyth, G. K. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv007 · Cited by 40,458 · cited 1×
“Transcriptome counts were normalized using the R package “limma” [20], and the gene expression values from TCGA and ICGC datasets were transformed as log2 (x + 1) counts.”
MethodclusterProfiler: an R Package for Comparing Biological Themes Among Gene Clusters
Yu, G., Wang, L.-G., Han, Y., & He, Q.-Y. (2012) · OMICS: A Journal of Integrative Biology · doi:10.1089/omi.2011.0118 · Cited by 36,259
WGCNA: an R package for weighted correlation network analysis
Langfelder, P., & Horvath, S. (2008) · BMC Bioinformatics · doi:10.1186/1471-2105-9-559 · Cited by 27,252
Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2022) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21708 · Cited by 17,196
Metascape provides a biologist-oriented resource for the analysis of systems-level datasets
Zhou, Y., Zhou, B., Pache, L., Chang, M., Khodabakhshi, A. H., Tanaseichuk, O., Benner, C., & Chanda, S. K. (2019) · Nature Communications · doi:10.1038/s41467-019-09234-6 · Cited by 14,611 · cited 1×
“org, accessed on 23 June 2022), a comprehensive database that plays an important role in the annotation and visualization of the gene list, was used for pathway analysis and protein–protein interaction (PPI) analysis [24].”
MethodRobust enumeration of cell subsets from tissue expression profiles
Newman, A. M., Liu, C. L., Green, M. R., Gentles, A. J., Feng, W., Xu, Y., Hoang, C. D., Diehn, M., & Alizadeh, A. A. (2015) · Nature Methods · doi:10.1038/nmeth.3337 · Cited by 13,224
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · cited 1×
“To explore the underlying effect of our model on the immune escape of ccRCC cells, we assessed the relationship between the RMC-based signature and ten immune checkpoints [61].”
MethodType, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516 · cited 1×
“Among these noncancer cells in the TME, tumor-infiltrating immune cells (TIICs) play a central role in predicting the metastasis and mortality of various tumors [12].”
BackgroundTIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells
Li, T., Fan, J., Wang, B., Traugh, N., Chen, Q., Liu, J. S., Li, B., & Liu, X. S. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0307 · Cited by 5,913
Elements of cancer immunity and the cancer–immune set point
Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352 · cited 1×
“Furthermore, dysfunction of TIICs is closely associated with prognosis and response to immunotherapy in cancer patients [13].”
BackgroundMaftools: efficient and comprehensive analysis of somatic variants in cancer
Mayakonda, A., Lin, D.-C., Assenov, Y., Plass, C., & Koeffler, H. P. (2018) · Genome Research · doi:10.1101/gr.239244.118 · Cited by 4,935 · cited 1×
“TMB was calculated as the number of variants/length of the exons (38 MB) using the “maftools” package [27].”
MethodAccessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
Hanahan, D., & Coussens, L. M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.022 · Cited by 4,632 · cited 1×
“Accumulating evidence has revealed that the TME is of great significance in tumor growth and progression [11].”
BackgroundMotzer, R. J., Escudier, B., Oudard, S., Hutson, T. E., Porta, C., Bracarda, S., Grünwald, V., Thompson, J. A., Figlin, R. A., Hollaender, N., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61039-9 · Cited by 3,019 · cited 1×
“Targeted therapeutic agents, such as vascular endothelial growth factor receptor inhibitors and mTOR inhibitors, can improve the survival of patients with ccRCC [6].”
BackgroundReimand, J., Isserlin, R., Voisin, V., Kucera, M., Tannus-Lopes, C., Rostamianfar, A., Wadi, L., Meyer, M., Wong, J., Xu, C., et al. (2019) · Nature Protocols · doi:10.1038/s41596-018-0103-9 · Cited by 1,970 · cited 1×
“We then used the EnrichmentMap package [26] in Cytoscape3.”
MethodRNA sequencing: the teenage years
Stark, R., Grzelak, M., & Hadfield, J. (2019) · Nature Reviews Genetics · doi:10.1038/s41576-019-0150-2 · Cited by 1,915 · cited 1×
“With the advancement of next-generation sequencing, RNA sequencing (RNA-seq) of bulk tissue has improved our understanding of tumor occurrence and development [16].”
BackgroundAnnual Report to the Nation on the Status of Cancer, 1975–2014, Featuring Survival
Jemal, A., Ward, E. M., Johnson, C. J., Cronin, K. A., Ma, J., Ryerson, A. B., Mariotto, A., Lake, A. J., Wilson, R., Sherman, R. L., et al. (2017) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djx030 · Cited by 1,556
International Variations and Trends in Renal Cell Carcinoma Incidence and Mortality
Znaor, A., Lortet-Tieulent, J., Laversanne, M., Jemal, A., & Bray, F. (2015) · European Urology · doi:10.1016/j.eururo.2014.10.002 · Cited by 984 · cited 1×
“Globally, the incidence and mortality of ccRCC have increased in the past few decades, resulting in a heavy burden on the healthcare system [3].”
BackgroundŞenbabaoğlu, Y., Gejman, R. S., Winer, A. G., Liu, M., Van Allen, E. M., de Velasco, G., Miao, D., Ostrovnaya, I., Drill, E., Luna, A., et al. (2016) · Genome Biology · doi:10.1186/s13059-016-1092-z · Cited by 968
Mast cell secretory granules: armed for battle
Wernersson, S., & Pejler, G. (2014) · Nature Reviews Immunology · doi:10.1038/nri3690 · Cited by 906 · cited 1×
“RMCs, an important type of TIMCs, are distinguished by their high content of electron-dense material evenly distributed throughout the major part of each granule in the cytoplasm [38].”
BackgroundTreatment of renal cell carcinoma: Current status and future directions
Barata, P. C., & Rini, B. I. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21411 · Cited by 831 · cited 1×
“However, many patients with ccRCC have no targetable mutations, and targeted therapy fails in patients with advanced ccRCC because of target tolerance [7].”
BackgroundGiraldo, N. A., Becht, E., Pagès, F., Skliris, G., Verkarre, V., Vano, Y., Mejean, A., Saint-Aubert, N., Lacroix, L., Natario, I., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2926 · Cited by 507
Progressive immune dysfunction with advancing disease stage in renal cell carcinoma
Braun, D. A., Street, K., Burke, K. P., Cookmeyer, D. L., Denize, T., Pedersen, C. B., Gohil, S. H., Schindler, N., Pomerance, L., Hirsch, L., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.02.013 · Cited by 504 · cited 1×
“Characterization of the composition and cellular states of TIICs helps to elucidate how the immune system might contribute to the immunotherapy response in advanced ccRCC [30].”
BackgroundBeyond conventional immune-checkpoint inhibition — novel immunotherapies for renal cell carcinoma
Braun, D. A., Bakouny, Z., Hirsch, L., Flippot, R., Van Allen, E. M., Wu, C. J., & Choueiri, T. K. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00455-z · Cited by 356
Metastasis and Immune Evasion from Extracellular cGAMP Hydrolysis
Li, J., Duran, M. A., Dhanota, N., Chatila, W. K., Bettigole, S. E., Kwon, J., Sriram, R. K., Humphries, M. P., Salto-Tellez, M., James, J. A., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0387 · Cited by 312 · cited 1×
“Tumor immune escape is a crucial step in avoiding antitumor immune responses during cancer metastasis [60].”
BackgroundTissue-resident memory T cells in breast cancer control and immunotherapy responses
Byrne, A., Savas, P., Sant, S., Li, R., Virassamy, B., Luen, S. J., Beavis, P. A., Mackay, L. K., Neeson, P. J., & Loi, S. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0333-y · Cited by 301 · cited 1×
“[35] suggested that patients with advanced breast cancer with high levels of tissue-resident memory T cells have elevated response rates to anti-PD1 therapy.”
BackgroundIL-33-mediated mast cell activation promotes gastric cancer through macrophage mobilization
Eissmann, M. F., Dijkstra, C., Jarnicki, A., Phesse, T., Brunnberg, J., Poh, A. R., Etemadi, N., Tsantikos, E., Thiem, S., Huntington, N. D., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10676-1 · Cited by 224 · cited 1×
“The analysis revealed that mast cell immune- and carcinoma-associated pathways were most abundant in the lowrisk group, including the VEGF signaling pathway [55], TGF beta signaling pathway [56], proteasome [57], cytokine–cytokine receptor interaction [58], and RCC, whereas autophagyassociated pathways were mainly enr…”
BackgroundImmunotherapy in Renal Cell Carcinoma: The Future Is Now
Deleuze, A., Saout, J., Dugay, F., Peyronnet, B., Mathieu, R., Verhoest, G., Bensalah, K., Crouzet, L., Laguerre, B., Belaud-Rotureau, M.-A., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072532 · Cited by 198 · cited 1×
“Furthermore, screening of biomarkers is key to select better treatments, reduce costs, and enhance the outcomes of advanced ccRCC [31].”
BackgroundGhatalia, P., Gordetsky, J., Kuo, F., Dulaimi, E., Cai, K. Q., Devarajan, K., Bae, S., Naik, G., Chan, T. A., Uzzo, R., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0621-1 · Cited by 159 · cited 2×
“Although some studies have constructed immunerelated predictive models that could influence ccRCC progression or prognosis [18,19,32], a risk signature based on distant metastasis-associated TIICs in ccRCC is still lacking.”
BackgroundSong, P., Li, W., Guo, L., Ying, J., Gao, S., & He, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.850745 · Cited by 152 · cited 1×
“Solid tumors consist of cancer cells surrounded by a complex tumor microenvironment (TME), including immune cells, stromal cells, cytokines, and extracellular matrix molecules [10].”
BackgroundMast cells and basophils in inflammatory and tumor angiogenesis and lymphangiogenesis
Marone, G., Varricchi, G., Loffredo, S., & Granata, F. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.03.088 · Cited by 139 · cited 1×
“The analysis revealed that mast cell immune- and carcinoma-associated pathways were most abundant in the lowrisk group, including the VEGF signaling pathway [55], TGF beta signaling pathway [56], proteasome [57], cytokine–cytokine receptor interaction [58], and RCC, whereas autophagyassociated pathways were mainly enr…”
BackgroundMoussay, E., Kaoma, T., Baginska, J., Muller, A., Van Moer, K., Nicot, N., Nazarov, P. V., Vallar, L., Chouaib, S., Berchem, G., et al. (2011) · Autophagy · doi:10.4161/auto.7.7.15454 · Cited by 125
Mast cells: A double-edged sword in cancer
Derakhshani, A., Vahidian, F., Alihasanzadeh, M., Mokhtarzadeh, A., Lotfi Nezhad, P., & Baradaran, B. (2019) · Immunology Letters · doi:10.1016/j.imlet.2019.03.011 · Cited by 111 · cited 1×
“TIMCs exert protumorigenic or antitumorigenic effects according to the type of carcinoma, degree of tumor progression, and location of TIMCs in tumor tissues [37].”
BackgroundRheostatic Functions of Mast Cells in the Control of Innate and Adaptive Immune Responses
Frossi, B., Mion, F., Tripodo, C., Colombo, M. P., & Pucillo, C. E. M. (2017) · Trends in Immunology · doi:10.1016/j.it.2017.04.001 · Cited by 103 · cited 1×
“RMCs are particularly important to the progression and treatment of various cancers [39].”
BackgroundPorcelli, L., Iacobazzi, R. M., Fonte, R., Serratì, S., Intini, A., Solimando, A. G., Brunetti, O., Calabrese, A., Leonetti, F., Azzariti, A., et al. (2019) · Cancers · doi:10.3390/cancers11030330 · Cited by 96 · cited 1×
“The analysis revealed that mast cell immune- and carcinoma-associated pathways were most abundant in the lowrisk group, including the VEGF signaling pathway [55], TGF beta signaling pathway [56], proteasome [57], cytokine–cytokine receptor interaction [58], and RCC, whereas autophagyassociated pathways were mainly enr…”
BackgroundPan, Q., Wang, L., Chai, S., Zhang, H., & Li, B. (2020) · Journal of Cancer · doi:10.7150/jca.37285 · Cited by 94 · cited 1×
“[42] demonstrated that RMCs can act as protective factors for patients with ccRCC; however, a model underlying RMCs has not been constructed.”
BackgroundSheng, X., Chen, H., Hu, B., Yao, X., Liu, Z., Yao, X., Guo, H., Hu, Y., Ji, Z., Luo, H., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2210 · Cited by 82 · cited 1×
“Substantial evidence has suggested that TMB has become an emerging biomarker of immunotherapy response among multiple solid tumors [59].”
BackgroundSelf-citationShimazaki, R., Takano, S., Satoh, M., Takada, M., Miyahara, Y., Sasaki, K., Yoshitomi, H., Kagawa, S., Furukawa, K., Takayashiki, T., et al. (2021) · Cellular Oncology · doi:10.1007/s13402-021-00614-z · Cited by 67 · cited 1×
“[46] suggested that high stromal CFB expression is associated with unfavorable clinical outcomes in patients with pancreatic ductal adenocarcinoma after surgery.”
BackgroundChen, S., Zhang, N., Jiang, L., Gao, F., Shao, J., Wang, T., Zhang, E., Yu, H., Wang, X., & Zheng, J. (2020) · International Journal of Cancer · doi:10.1002/ijc.33288 · Cited by 59 · cited 1×
“In contrast to other studies that simply used common clinical variables to build nomograms in ccRCC [53,54], we integrated independent prognostic factors to construct the nomogram, improving the significance of the predictive model.”
ResultXia, Q., Xun, Y., Lu, J., Liu, C., Sun, J., Li, C., & Wang, S. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/6634247 · Cited by 58 · cited 1×
“In contrast to other studies that simply used common clinical variables to build nomograms in ccRCC [53,54], we integrated independent prognostic factors to construct the nomogram, improving the significance of the predictive model.”
ResultSelf-citationTOM1L1 drives membrane delivery of MT1-MMP to promote ERBB2-induced breast cancer cell invasion
Chevalier, C., Collin, G., Descamps, S., Touaitahuata, H., Simon, V., Reymond, N., Fernandez, L., Milhiet, P.-E., Georget, V., Urbach, S., et al. (2016) · Nature Communications · doi:10.1038/ncomms10765 · Cited by 53 · cited 1×
“[51] reported that TOM1L1 promotes ERBB2-induced breast cancer cell invasion.”
BackgroundHua, X., Chen, J., Yang, S., & Liang, C. Y. (2020) · Aging · doi:10.18632/aging.102746 · Cited by 51 · cited 1×
“Although some studies have constructed immunerelated predictive models that could influence ccRCC progression or prognosis [18,19,32], a risk signature based on distant metastasis-associated TIICs in ccRCC is still lacking.”
BackgroundSelf-citationYang, S., Lu, J., Chen, X., Liang, C. Y., Luo, P., Qin, C., & Zhang, J. (2018) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-018-2808-0 · Cited by 50 · cited 1×
“In addition, considering the possible role of autophagy in ccRCC distant metastasis, which is in agreement with the results of our previous study [62], we further discovered that RGS19 shared the highest correlation with the risk score, which was likely the key ATG regulated by the risk model.”
ResultSelf-citationLeslie, M. (2007) · Science · doi:10.1126/science.317.5838.614 · Cited by 47 · cited 11×
“Abbreviations ATGs: autophagy-related genes; AIC: Akaike information criterion; AUC: area under the curve; CTLA-4: cytotoxic T-lymphocyte antigen-4; DCA: decision curve analysis; DMAGs: distant metastasis-associated marker genes; DFS: disease-free survival; GSEA: gene set enrichment analysis; IHC: immunohistochemistry…”
BackgroundInfluentialSznurkowski, J. J., Żawrocki, A., & Biernat, W. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1511-x · Cited by 45 · cited 1×
“In vulvar squamous cell carcinoma, subtypes of cytotoxic lymphocytes and NK cells infiltrating cancer nests are associated with patient prognosis [34].”
BackgroundSerzan, M. T., & Atkins, M. B. (2021) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2021.76 · Cited by 45
Cooley, L. S., Rudewicz, J., Souleyreau, W., Emanuelli, A., Álvarez-Arenas, A., Clarke, K., Falciani, F., Dufies, M., Lambrechts, D., Modave, E., et al. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01416-5 · Cited by 44 · cited 1×
“[48] suggested that patients with RCC with increased CFB levels have faster disease progression and lower survival rates than those with decreased CFB levels.”
BackgroundNK cells in the brain: implications for brain tumor development and therapy
Balatsoukas, A., Rossignoli, F., & Shah, K. (2022) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2021.12.008 · Cited by 38 · cited 1×
“For example, tumor-infiltrating macrophages have been reported to blunt the antitumor response in glioblastoma by secreting TGF-β and IL-10 and recruiting regulatory T (Treg) cells [33].”
BackgroundFacts and Hopes for Immunotherapy in Renal Cell Carcinoma
Yao, C., Zhang, T., Wu, T., & Brugarolas, J. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2372 · Cited by 37 · cited 1×
“Recently, the clinical application of novel immunotherapies including cytokines, immune checkpoint inhibitors (ICIs), and adoptive cells has dramatically improved the outcomes of patients with metastatic ccRCC [4,8].”
BackgroundSelf-citationGirirajan, S., Hauck, P. M., Williams, S. R., Vlangos, C. N., Szomju, B. B., Solaymani-Kohal, S., Mosier, P. D., White, K. L., McCoy, K. L., & Elsea, S. H. (2008) · Mammalian Genome · doi:10.1007/s00335-008-9100-6 · Cited by 31 · cited 1×
“In cutaneous squamous cell carcinoma, TOM1L1 expression levels are decreased and related to precursor lesions [52].”
BackgroundEmerging Targets in Clear Cell Renal Cell Carcinoma
Chen, Y., Rini, B. I., & Beckermann, K. E. (2022) · Cancers · doi:10.3390/cancers14194843 · Cited by 28 · cited 4×
“Accumulating evidence suggests that immunotherapy plays a non-negligible role in the treatment of patients with ccRCC with distant metastases [4,29].”
BackgroundInfluentialImmunotherapy in the Treatment of Urothelial Bladder Cancer: Insights From Single-Cell Analysis
Zang, J., Ye, K., Yang, F., Zhang, R., Chen, H., & Zhuang, G. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.696716 · Cited by 27 · cited 1×
“Emerging single-cell technologies, which provide a high-resolution tumor immune landscape, could exert a complementary effect in principle [17].”
BackgroundSelf-citationIdentification of a Metastasis-Associated Gene Signature of Clear Cell Renal Cell Carcinoma
Gao, S., Yan, L., Zhang, H., Fan, X., Jiao, X., & Shao, F. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2020.603455 · Cited by 27 · cited 1×
“Compared to other studies that merely utilized bulk RNA-seq to filter key genes in metastatic ccRCC [44,45], ignoring the complex interaction of tumor cells and the associated nontumor constituents in TME, we identified ccRCC distant metastatic marker genes after systematic analysis of scRNA-seq data.”
ResultMast Cells Resting-Related Prognostic Signature in Hepatocellular Carcinoma
Zhang, H., Sun, L., & Hu, X. (2021) · Journal of Oncology · doi:10.1155/2021/4614257 · Cited by 26 · cited 1×
“For instance, a high RMC density is associated with a favorable prognosis in hepatocellular carcinoma [40].”
BackgroundIdentification and Validation of Autophagy-Related Genes in Vitiligo
Yang, Y., Wu, X., Lu, X., Wang, C., Xiang, L. F., & Zhang, C. (2022) · Cells · doi:10.3390/cells11071116 · Cited by 26 · cited 1×
“RGS19 codes a guanosine triphosphatase-activating protein related to autophagy dysregulation [63].”
BackgroundCui, Y., Shen, T., Xu, F., Zhang, J., Wang, Y., Wu, J., Bu, H., Fu, D., Fang, B., Lv, H., et al. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02626-7 · Cited by 24 · cited 1×
“[43] suggested that the infiltration of RMCs was negatively linked with the histological grade of ccRCC, the significance of RMCs in ccRCC metastasis has not been investigated.”
BackgroundThe prognostic value of plasma complement factor B (CFB) in thyroid carcinoma
Wu, P., Shi, J., Sun, W., & Zhang, H. (2021) · Bioengineered · doi:10.1080/21655979.2021.2005745 · Cited by 20 · cited 1×
“[47] found that the expression of CFB in patients with N1 stage thyroid carcinoma was higher than that in those with N0 stage disease.”
BackgroundWesterberg, C. M., Hägglund, H., & Nilsson, G. P. (2012) · Cell Death and Disease · doi:10.1038/cddis.2012.157 · Cited by 20 · cited 1×
“The analysis revealed that mast cell immune- and carcinoma-associated pathways were most abundant in the lowrisk group, including the VEGF signaling pathway [55], TGF beta signaling pathway [56], proteasome [57], cytokine–cytokine receptor interaction [58], and RCC, whereas autophagyassociated pathways were mainly enr…”
BackgroundZhang, C., Li, Y., Qian, J., Zhu, Z., Huang, C., He, Z., Zhou, L., & Gong, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1020729 · Cited by 18
Wang, Y., Liu, S., Chen, Y., Zhu, B., & Xing, Q. (2022) · World Journal of Oncology · doi:10.14740/wjon1446 · Cited by 17 · cited 1×
“PPP1R18 is highly expressed in ccRCC cell lines and tissues [50].”
BackgroundIdentification of key genes and pathways associated with resting mast cells in meningioma
Xie, H., Yuan, C., Ding, X., Li, J.-J., Li, Z., & Lu, W. (2021) · BMC Cancer · doi:10.1186/s12885-021-08931-0 · Cited by 17 · cited 1×
“[41] suggested that the distribution of RMCs in meningioma tissues is significantly higher than that in normal controls.”
BackgroundDou, Q., Gao, S., Gan, H., Kang, Z., Zhang, H., Yang, Y., & Tong, H. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.692535 · Cited by 14 · cited 1×
“Compared to other studies that merely utilized bulk RNA-seq to filter key genes in metastatic ccRCC [44,45], ignoring the complex interaction of tumor cells and the associated nontumor constituents in TME, we identified ccRCC distant metastatic marker genes after systematic analysis of scRNA-seq data.”
ResultMeng, L.-Y., Wang, M., Du, Z., Fang, Z., Wu, B., Wu, J., Xie, W., Shen, J., Zhu, T.-X., Xu, X., et al. (2017) · BioMed Research International · doi:10.1155/2017/9592501 · Cited by 11 · cited 1×
“[49] reported that PPP1R18 activates LCN2 expression, which is related to esophageal cancer invasion.”
BackgroundLiu, Y., Lou, W., Chen, G., Ding, B., Kuang, J., Zhang, Y., Wang, C., Duan, S., Deng, Y., & Lu, X. (2021) · Bioengineered · doi:10.1080/21655979.2021.1971035 · Cited by 10 · cited 1×
“The upregulated expression of RGS19 was associated with poor prognosis of bladder cancer patients [64].”
Background
Cited by
Zhu, Z., Jin, Y., Zhou, J., Chen, F., Chen, M., Gao, Z., Hu, L., Xuan, J., Li, X., Song, Z., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02059-y · Cited by 99
“Although the high-risk group shows lower infiltration of RMCs, higher tumor mutation burden (TMB), and worse prognosis, they are more sensitive to immune therapy with anti-PD1 and anti-CTLA-4, while the low-risk group responds better to immune therapy with anti-PD-L1 [44].”
BackgroundMethodSelf-citationPredicting bladder cancer survival with high accuracy: insights from MAPK pathway-related genes
Cheng, G., Zhou, Z., Li, S., Yang, S., Wang, Y., Ye, Z., & Ren, C. (2024) · Scientific Reports · doi:10.1038/s41598-024-61302-0 · Cited by 14
“Prognostic differences between different risk subgroups are often driven by underlying molecular mechanisms and pathways 39,40 .”
Owoicho, A. M., Ogenyi, D. O., Zhilenkova, A. V., Essogmo, F. E., Tchawe, Y. S. N., Uchendu, I. K., Pascal, A. M., Nikitina, N. M., Rusanov, A. S., Sanikovich, V. D., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms26010265 · Cited by 15
Tomita, Y., Motzer, R. J., Choueiri, T. K., Rini, B. I., Miyake, H., Oya, M., Albiges, L. K., Aizawa, M., Umeyama, Y., Wang, J., et al. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.102034 · Cited by 12
SCARB2 associates with tumor-infiltrating neutrophils and predicts poor prognosis in breast cancer
Zhang, D., Fang, J., Shan, J., Xu, L., Wu, Y., Lu, B., Zhang, X., Wang, C., Sun, P., & Wang, Q. (2024) · Breast Cancer Research and Treatment · doi:10.1007/s10549-024-07401-y · Cited by 7
“TME plays an essential role in breast cancer development [21], and TIICs are instrumental in disease progression and patient prognosis for various malignancies [22].”
Metadata
- Authors
- Su, Y., Zhang, T., Lu, J., Qian, L., Fei, Y., Zhang, L., Fan, S., Zhou, J., Tang, J., Chen, H., & Liang, C.
- Affiliations
- Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei 230031, China
- Shanghai Jiao Tong University (CN)
- University of Oxford (GB)
- Anhui Medical University (CN)
- Corresponding author
- Chen, Haige
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2023-01-01
- Volume
- 12
- Issue
- 1
- Pages
- 180
- ISSN
- 2073-4409 (ISSN-L)
- PMC
- PMC9818872
- OpenAlex
- W4313472298
- Cited by
- 20
- References
- 64
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 10 · 2023: 4
- FWCI
- 3.67
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cells (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Anhui Medical University Basic and Clinical Cooperative Research Promotion Project (2020xkjT031, 202110366035, 2017ZHYX02)
- National Level Innovation Training Program for Chinese College Students of the Ministry of Education of the People’s Republic of China (2020xkjT031, 202110366035, 2017ZHYX02)
- Scientific Research Foundation of the Institute for Translational Medicine of Anhui Province (2020xkjT031, 202110366035, 2017ZHYX02)
- Topics
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
- Keywords
- clear cell renal cell carcinoma, resting mast cells, distant metastasis, prognostic gene panel, immunotherapy response prediction, tumor-infiltrating immune cells, CFB, tumor mutational burden, anti-PD-1, anti-CTLA-4, PD-L1 inhibitors, immune heterogeneity, risk stratification
- MeSH terms
- Carcinoma, Carcinoma, Renal Cell, Humans, Immunotherapy, Kidney Neoplasms, Mast Cells, Prognosis, Adaptor Proteins, Signal Transducing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.